This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

ASCO Again Aims to Plug Information Leak

"We commend ASCO for understanding industry concerns and working quickly to find a fair solution that can be acceptable to physicians, investors and publicly traded companies," says Neil Cohen, a Genentech spokesman.

Says SG Cowen analyst Eric Schmidt: "This isn't a bad thing as long as there is equal and fair dissemination of the research abstracts. The past couple of years have been a real disaster for ASCO."

Scott Gottlieb, a doctor and fellow at the American Enterprise Institute, disagrees. Gottlieb believes ASCO should have decided to make a general public release of its abstracts in advance of the annual meeting. Instead, ASCO's actions bolster his view that the group is more interested in preserving the importance of its meeting rather than actually helping doctors treat patients with cancer.

"It seems ASCO is still in the business of restricting information, but now nobody can have it," says Gottlieb. "It still presumes average people are too stupid to interpret bottom-line results without the help of the conference. This will probably hurt the quality of the conference for its members, so I'm surprised [ASCO] did it."

ASCO's new policy does not make any mention of its embargo policy, which prohibits the media from publishing research-abstract data before the meeting, and even extends the prohibition to any information gleaned from analyst reports. ASCO has barred TheStreet from attending its meeting under a media credential for the last two years because TheStreet reported on ASCO research data contained in Wall Street analysts' notes, although the information was "embargoed" by the group.
3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
CTIC $1.18 0.00%
IMCL $1.18 0.00%
AAPL $118.88 0.00%
FB $105.74 0.00%
GOOG $748.28 0.00%


Chart of I:DJI
DOW 17,812.19 +19.51 0.11%
S&P 500 2,089.14 +2.55 0.12%
NASDAQ 5,102.8080 +0.33 0.01%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs